Merck Animal Health (MRK) Receives USDA Approval of Canine Flu Bivalent Vaccine
- Stocks close with gains, led by Dow as investors look for rate insight
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Robinhood (HOOD) rises after saying it plans to launch a credit card for US consumers
- Short sellers target Reddit shares as stock slips
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine
October 7, 2016 4:05 PM EDTFirst Vaccine to Offer Protection Against Both Strains of Canine Influenza
MADISON, N.J.--(BUSINESS WIRE)-- Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced that the U.S. Department of Agriculture has approved a license for Nobivac® Canine Flu Bivalent vaccine the first vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8.
Merck Animal Health has a rich history of vaccine development supported by a wealth of... More